Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Next Previous
Trial Profile

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zorevunersen (Primary)
  • Indications Dravet syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ADMIRAL; STK-001-DS-102 (ADMIRAL)
  • Sponsors Stoke Therapeutics

Most Recent Events

  • 03 Sep 2026 According to the Stoke Therapeutics media release, data from the trial were presented at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece.
  • 03 Sep 2026 Results presented in the Stoke Therapeutics Media Release
  • 01 Sep 2026 According to the Stoke Therapeutics media release, data form this study will be presented data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top